罗氏|罗氏活性药物成分的环境风险评估

罗氏活性药物成分(API)的环境风险评估(ERA)

爱游戏体育博彩可持续发展下载中心

PDF"],["2022/10","Xofluza - Baloxavir marboxil ","ERA","PDF"],["2022/09","Gavreto - Ralsetinib ","ERA","PDF"],["2021/05\t","Alecensa - Alectinib\t","ERA","PDF"],["2021/05\t","Cellcept - Mycophenolate mofetil\t","ERA","PDF"],["2021/05\t","Copegus - Ribavirin\t","ERA","PDF"],["2021/05\t","Cotellic - Cobimetinib\t","ERA","PDF"],["2021/05\t","Erivedge - Vismodegib\t","ERA","PDF"],["2021/05\t","Esbriet - Pirfenidone\t","ERA","PDF"],["2021/05\t","Evrysdi - Risdiplam\t","ERA","PDF"],["2021/05\t","Madopar - Benserazide\t","ERA","PDF"],["2021/05\t","Madopar - Levodopa\t","ERA","PDF"],["2021/06\t","Enspryng - Satralizumab\t","ERA","PDF"],["2021/06\t","Invirase - Saquinavir mesylate\t","ERA","PDF"],["2021/06\t","Mircera - C.E.R.A.\t","ERA","PDF"],["2021/06\t","Pegasys - Peginterferon a-2a\t","ERA","PDF"],["2021/06\t","Rocephin - Lidocaine\t","ERA","PDF"],["2021/06\t","Tamiflu - Oseltamivir\t","ERA","PDF"],["2021/06\t","Tarceva – Erlotinib\t","ERA","PDF"],["2021/06\t","Xeloda - Capecitabine\t","ERA","PDF"],["2021/06\t","Zelboraf - Vemurafenib\t","ERA","PDF"],["2021/08\t","Avastin - Bevacizumab\t","ERA","PDF"],["2021/08\t","Fuzeon - Enfuvirtide\t","ERA","PDF"],["2021/08\t","Gazyvaro - Obinutuzumab\t","ERA","PDF"],["2021/08\t","Hemlibra - Emicizumab\t","ERA","PDF"],["2021/08\t","Herceptin - Trastuzumab\t","ERA","PDF"],["2021/08\t","Lucentis - Ranibizumab\t","ERA","PDF"],["2021/08\t","MabThera - Rituximab\t","ERA","PDF"],["2021/08\t","NeoRecormon - Epoetin Beta\t","ERA","PDF"],["2021/08\t","Ocrevus - Ocrelizumab\t","ERA","PDF"],["2021/08\t","Perjeta - Pertuzumab\t","ERA","PDF"],["2021/08\t","Pulmozyme - Dornase alfa\t","ERA","PDF"],["2021/08\t","Roferon-A - Interferon alfa-2a\t","ERA","PDF"],["2021/08\t","Rozlytrek - Entrectinib\t","ERA","PDF"],["2021/08\t","Tecentriq- Atezolizumab\t","ERA","PDF"],["2022/06\t","Rocephin - Ceftriaxone\t","ERA","PDF"],["2021/10\t","Bondronat - Ibandronate\t","ERA","PDF"],["2021/10\t","Bonviva - Ibandronate\t","ERA","PDF"],["2021/10\t","Rivotril - Clonazepam\t","ERA","PDF"],["2021/10\t","Valcyte - Valganciclovir\t","ERA","PDF"],["2021/10\t","Valium - Diazepam\t","ERA","PDF"],["2021/11\t","Kadcyla - Trastuzumab emtansine\t","ERA","PDF"],["2021/11\t","Polivy - Polatuzumab vedotin\t","ERA","PDF"],["2021/11\t","Roaccutane - Isotretinoin\t","ERA","PDF"],["2021/11\t","Ronapreve - Casirivimab + Imdevimab\t","ERA","PDF"],["2021/12\t","Actemra/RoActemra - Tocilizumab\t","ERA","PDF"],["2022/06\t","Bactrim - Trimethoprim\t","ERA","PDF"],["2022/06\t","Bactrim - Sulfamethoxazole\t","ERA","PDF"],["2022/06\t","Lunsumio - Mosunetuzumab\t","ERA","PDF"]]" slot="left" uid="acc2b992-f103-43ea-bd88-a5bd43ad300c" id="acc2b992-f103-43ea-bd88-a5bd43ad300c" storyid="77473937" class="sc-roche-responsive-table-h hydrated">

日期

2022/10

2022/09

2021/05

2021/06

2021/08

2022/06

2021/10

2021/11

2021/12

2022/06

标题

Vabysmo - Faricimab

Xofluza - Baloxavir marboxil

Gavreto - Ralsetinib

Alecensa - Alectinib

Cellcept -霉酚酸酯

利巴韦林

Cotellic - Cobimetinib

Erivedge - Vismodegib

Esbriet -吡非尼酮

Evrysdi - Risdiplam

美多巴-苯拉齐特

美多巴-左旋多巴

Enspryng - Satralizumab

甲磺酸沙奎那韦

米拉- C.E.R.A.

Pegasys - peg干扰素a-2a

罗塞芬-利多卡因

达菲-奥司他韦

特罗凯-厄洛替尼

希罗达-卡培他滨

Zelboraf - Vemurafenib

阿瓦斯汀-贝伐珠单抗

Fuzeon - Enfuvirtide

Gazyvaro - Obinutuzumab

Hemlibra - Emicizumab

赫赛汀-曲妥珠单抗

Lucentis - Ranibizumab

MabThera -美罗华

NeoRecormon -促红细胞生成素

Ocrevus - Ocrelizumab

Perjeta - Pertuzumab

Pulmozyme - Dornase

Roferon-A -干扰素α -2a

Rozlytrek - Entrectinib

Tecentriq——Atezolizumab

罗头孢芬-头孢曲松

Bondronat - Ibandronate

Bonviva - Ibandronate

利伏特里-氯硝西泮

Valganciclovir

安定——安定

曲妥珠单抗-伊坦辛

Polatuzumab vedotin

异维甲酸

Ronapreve - Casirivimab + Imdevimab

Actemra/RoActemra - Tocilizumab

Bactrim -甲氧苄啶

磺胺甲恶唑

Lunsumio - Mosunetuzumab

类型

时代

下载

PDF

发布环境风险评估(ERA)摘要是罗氏致力于更好地理解药物在环境中的问题(PiE)的一部分。研究新药物在开发过程中的生物降解性和初始生态毒性。为了注册，根据相关法规的要求，根据长期环境影响和先进的环境命运数据，制定了完整的最先进的环境风险评估。虽然不是监管要求，但罗氏也会调查较老的药物，通常规模比较简单，以评估其环境风险。

下载

罗氏关于药物在环境中的地位(PiE)

PDF

发现更多的

环境风险评估指南

爱游戏ayx官方